SRRK: Scholar Rock Holding Corp.
About
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Current Value
$27.981 Year Return
Current Value
$27.981 Year Return
Key Details
Market Cap
$2.61B
P/E Ratio
-11.29
1Y Stock Return
134.91%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
28.2
Strategies that include SRRK
Stock's related to SRRK
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NAPA | 93.64% | $1.63B | +9.61% | 0.00% |
| OCFT | 49.19% | $80.95M | -30.38% | 0.00% |
| ALTM | 47.78% | $5.58B | -23.79% | 0.00% |
| CRNC | 45.82% | $124.16M | -82.36% | 0.00% |
| VSTO | 37.53% | $2.58B | +71.61% | 0.00% |
| SUNS | 37.09% | $105.89M | +35.31% | 1.37% |
| ALT | 36.91% | $531.30M | +194.09% | 0.00% |
| AROW | 36.83% | $546.36M | +34.05% | 4.19% |
| ALLO | 36.41% | $444.50M | -24.82% | 0.00% |
| WSR | 35.70% | $738.93M | +33.24% | 3.37% |
| AVXL | 35.44% | $698.71M | +22.62% | 0.00% |
| HTBK | 34.55% | $645.52M | +24.17% | 4.92% |
| RICK | 34.48% | $440.11M | -13.68% | 0.51% |
| PTGX | 34.44% | $2.30B | +122.64% | 0.00% |
| PSTL | 34.05% | $326.85M | +0.29% | 6.95% |
| SRI | 33.99% | $166.13M | -63.46% | 0.00% |
| BWB | 33.94% | $406.17M | +41.99% | 0.00% |
| OLP | 33.86% | $617.02M | +46.60% | 6.26% |
| APD | 33.84% | $72.92B | +18.69% | 2.14% |
| HONE | 33.76% | $572.67M | +17.97% | 2.43% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MD | <0.01% | $1.25B | +67.55% | 0.00% |
| SPHR | -<0.01% | $1.48B | +20.48% | 0.00% |
| CSAN | -<0.01% | $3.57B | -47.92% | 4.24% |
| NOVA | 0.01% | $429.84M | -67.33% | 0.00% |
| FRSH | 0.01% | $4.39B | -20.05% | 0.00% |
| LAZ | -0.01% | $4.81B | +106.38% | 3.64% |
| DX | 0.01% | $991.29M | +9.75% | 12.54% |
| SFBS | -0.01% | $5.11B | +85.58% | 1.29% |
| LADR | 0.02% | $1.49B | +6.01% | 7.91% |
| AMKR | -0.02% | $6.26B | -6.38% | 1.25% |
| MNKD | 0.02% | $1.89B | +84.91% | 0.00% |
| OTEX | -0.03% | $7.59B | -26.30% | 3.55% |
| TGI | -0.03% | $1.45B | +73.06% | 0.00% |
| ESE | -0.03% | $3.77B | +40.05% | 0.22% |
| WGO | -0.03% | $1.67B | -12.54% | 2.20% |
| GPN | -0.03% | $29.20B | +2.38% | 0.87% |
| ATEX | -0.04% | $617.94M | +5.94% | 0.00% |
| ANAB | 0.04% | $607.66M | +40.93% | 0.00% |
| MT | 0.06% | $20.01B | +6.79% | 1.99% |
| BAM | 0.06% | $23.31B | +66.79% | 2.62% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UVE | -43.49% | $631.63M | +36.40% | 2.86% |
| HCI | -41.24% | $1.16B | +29.00% | 1.48% |
| RNR | -37.87% | $13.74B | +23.09% | 0.58% |
| EG | -32.07% | $15.92B | -8.98% | 2.02% |
| ACGL | -27.55% | $36.00B | +16.84% | 0.00% |
| CB | -27.00% | $114.43B | +26.00% | 1.24% |
| HRTG | -26.22% | $371.89M | +58.22% | 0.00% |
| RLI | -26.16% | $8.01B | +29.25% | 0.64% |
| ACIC | -26.13% | $631.49M | +58.21% | 0.00% |
| AIZ | -25.20% | $11.24B | +33.00% | 1.31% |
| ALL | -24.67% | $52.06B | +45.67% | 1.85% |
| PGR | -20.13% | $149.10B | +57.29% | 0.45% |
| AXS | -19.72% | $7.14B | +55.12% | 2.06% |
| L | -19.16% | $18.32B | +23.54% | 0.30% |
| CINF | -18.69% | $23.54B | +48.25% | 2.10% |
| DUK | -18.48% | $87.74B | +26.37% | 3.65% |
| HALO | -18.00% | $5.70B | +15.25% | 0.00% |
| CNA | -17.92% | $13.16B | +23.03% | 3.61% |
| PLMR | -17.82% | $2.84B | +79.77% | 0.00% |
| TRV | -17.80% | $58.86B | +48.10% | 1.59% |
ETF's related to SRRK
News
Finnhub
CAMBRIDGE - Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where...
Yahoo
CAMBRIDGE, Mass., November 15, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its common stock to four newly hired employees, consisting of inducement stock options to p
Finnhub
Ownership Submission FORM 4 Check this box if no longer...
Yahoo
Scholar Rock Holding Corp (SRRK) reports significant progress in its SAPPHIRE study and financial growth, setting the stage for future market expansion.
Yahoo
CAMBRIDGE, Mass., November 12, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2024.
SeekingAlpha
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ETCompany ParticipantsJay Backstrom - President...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.